[go: up one dir, main page]

WO2025038666A3 - Composés et méthodes de traitement de la dépendance - Google Patents

Composés et méthodes de traitement de la dépendance Download PDF

Info

Publication number
WO2025038666A3
WO2025038666A3 PCT/US2024/042162 US2024042162W WO2025038666A3 WO 2025038666 A3 WO2025038666 A3 WO 2025038666A3 US 2024042162 W US2024042162 W US 2024042162W WO 2025038666 A3 WO2025038666 A3 WO 2025038666A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
methods
addiction
treating addiction
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/042162
Other languages
English (en)
Other versions
WO2025038666A2 (fr
Inventor
Ian Jenkins
Robert TINDER
Vaishnavi Narayan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gatc Health Corp
Original Assignee
Gatc Health Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gatc Health Corp filed Critical Gatc Health Corp
Publication of WO2025038666A2 publication Critical patent/WO2025038666A2/fr
Publication of WO2025038666A3 publication Critical patent/WO2025038666A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des modes de réalisation de la présente invention comprennent de petites molécules thérapeutiques destinées à être utilisées dans le traitement de l'addiction et de troubles neurologiques. Les petites molécules thérapeutiques peuvent agir en tant qu'agonistes du récepteur 5-HT2A et/ou agonistes du récepteur 5-HT6. Contrairement aux agonistes classiques, les composés de l'invention ne provoquent pas d'effets secondaires psychédéliques. Dans certains aspects, les composés sont utilisés pour traiter une affection ou une addiction. Dans certains aspects, les composés favorisent la neuroplasticité.
PCT/US2024/042162 2023-08-13 2024-08-13 Composés et méthodes de traitement de la dépendance Pending WO2025038666A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363532417P 2023-08-13 2023-08-13
US63/532,417 2023-08-13

Publications (2)

Publication Number Publication Date
WO2025038666A2 WO2025038666A2 (fr) 2025-02-20
WO2025038666A3 true WO2025038666A3 (fr) 2025-03-27

Family

ID=94632657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/042162 Pending WO2025038666A2 (fr) 2023-08-13 2024-08-13 Composés et méthodes de traitement de la dépendance

Country Status (1)

Country Link
WO (1) WO2025038666A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000086A1 (fr) * 1991-06-26 1993-01-07 Smithkline Beecham Plc Utilisation de derives de tetrahydrocarbazone comme agonistes de recepteurs du type 5-ht¿1?
US20090170882A1 (en) * 2004-06-30 2009-07-02 Dashyant Dhanak Methods and compositions
US20130065902A1 (en) * 2010-03-22 2013-03-14 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
US11414423B1 (en) * 2019-02-27 2022-08-16 The Regents Of The University Of California Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000086A1 (fr) * 1991-06-26 1993-01-07 Smithkline Beecham Plc Utilisation de derives de tetrahydrocarbazone comme agonistes de recepteurs du type 5-ht¿1?
US20090170882A1 (en) * 2004-06-30 2009-07-02 Dashyant Dhanak Methods and compositions
US20130065902A1 (en) * 2010-03-22 2013-03-14 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
US11414423B1 (en) * 2019-02-27 2022-08-16 The Regents Of The University Of California Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LISTABARTH STEPHAN, VYSSOKI BENJAMIN, MARCULESCU RODRIG, GLEISS ANDREAS, GROEMER MAGDALENA, TROJER ARMIN, HARRER CHRISTINE, WEBER : "Can thiamine substitution restore cognitive function in alcohol use disorder?", ALCOHOL AND ALCOHOLISM, PERGAMON, OXFORD, GB, vol. 58, no. 3, 1 May 2023 (2023-05-01), GB , pages 315 - 323, XP093296257, ISSN: 0735-0414, DOI: 10.1093/alcalc/agad017 *

Also Published As

Publication number Publication date
WO2025038666A2 (fr) 2025-02-20

Similar Documents

Publication Publication Date Title
Sprott et al. Pain treatment of fibromyalgia by acupuncture
Andersson Potential benefits of muscarinic M3 receptor selectivity
NO20091888L (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
WO2004084835A3 (fr) Traitement de troubles immunologiques a l'aide de l'interleukine-21/ du recepteur de l'interleukine-21
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
FR12C0052I1 (fr)
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
WO2001087328A3 (fr) Inhibiteurs d"interleukine 1 dans le traitement de maladies
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
WO2008153632A3 (fr) Compositions et méthodes de traitement de l'obésité et de troubles connexes
WO2002094196A3 (fr) Methode de traitement de cancers associes a des niveaux de her-2 eleves
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
Ten Hove et al. Neuronal innervation of the intestinal crypt
PT1107795E (pt) Tiomolibdato associado com pelo menos um hidrato de carbono e o seu uso para evitar ou tratar doencas caracterizadas por uma vascularizacao tais como cancro degeneracao macular do tipo humido artrite reumatoide
EP1108426A3 (fr) Utilisation d'agonistes des prostaglandines pour traiter les troubles de l'érection et l'impotence
WO2025038666A3 (fr) Composés et méthodes de traitement de la dépendance
MX2022015764A (es) Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis.
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
BR9912581A (pt) Processos para tratar ou prevenir um distúrbio causado por disfunção da motilidade gastrointestinal em um humano e para elicitar um efeito procinético em um humano, e, composição farmacêutica
WO2005061002A3 (fr) Composition et procedes pour la modulation de l'activite du systeme nerveux central
WO2023159048A3 (fr) Inhibiteur de stat3 à petites molécules pour traitement du cancer du sein triple négatif
WO2004100899A3 (fr) Utilisation de secretine dans les traitements de troubles associes a l'amygdale
CA2246560A1 (fr) Methodes d'administration d'un antagoniste du recepteur ampa pour traiter les dyskinesies associees a la therapie par un agoniste de la dopamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24854830

Country of ref document: EP

Kind code of ref document: A2